Jubilant Cadista — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Jubilant Cadista, founded in 2007 and headquartered in Salisbury, Maryland, is a subsidiary of India's Jubilant Pharmova Limited, operating as a key US generics arm. The company develops, manufactures, and markets a broad portfolio of generic finished dosage forms, leveraging the integrated supply chain and R&D capabilities of its parent organization. Its business model is centered on cost-effective manufacturing and a customer-centric approach to serve the competitive US generic drug market. As a private entity, it focuses on operational excellence and quality to capture market share in established therapeutic areas.

Central Nervous SystemCardiovascularAnti-infectivesGastrointestinalMetabolic Disorders

Technology Platform

Integrated generic drug development and manufacturing platform focusing on formulation development, bioequivalence, regulatory submissions (ANDA), and cost-effective cGMP production of finished dosage forms.

Opportunities

The ongoing wave of brand-name drug patent expiries creates a steady stream of new generic opportunities.

Additionally, healthcare system cost pressures ensure sustained demand for affordable generic alternatives, favoring efficient manufacturers.

Building a reputation for reliable quality and supply can secure preferred status with large distributors and pharmacy chains.

Risk Factors

The primary risk is severe price erosion due to intense competition in the US generics market, which rapidly diminishes profitability.

Significant regulatory and compliance risk exists, as FDA actions against manufacturing facilities can disrupt supply and damage the brand.

The company is also dependent on the strategic decisions and operational performance of its parent company, Jubilant Pharmova.

Competitive Landscape

Jubilant Cadista competes in the highly fragmented and competitive US generic pharmaceutical market against large players like Teva, Sandoz (Novartis), Mylan (Viatris), and Sun Pharma, as well as numerous smaller generic firms. Competition is primarily on price, product portfolio breadth, and supply reliability, with thin margins being the industry norm.

More companies in United States →